Embedded Files
DelveInsight's "Brain Metastases Pipeline Analysis 2025" delivers extensive intelligence on over 40 pharmaceutical firms and more than 45 investigational medications within the Brain Metastases development arena. The analysis encompasses profiles of Brain Metastases pipeline therapeutic candidates, spanning both clinical and preclinical phases. Brain Metastases pipeline analysis also covers therapeutics evaluation by product category, developmental phase, administration method, and molecular classification. The report also spotlights dormant pipeline products in this therapeutic area.
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! - Brain Metastases Pipeline Outlook Report
Primary Highlights from the Brain Metastases Pipeline Analysis
Primary Highlights from the Brain Metastases Pipeline Analysis
On November 21, 2025, Memorial Sloan Kettering Cancer Center initiated an investigation to see if Cs-131 brachytherapy is effective in individuals with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after surgery. The researchers will compare Cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. The researchers will compare both the effectiveness and safety of the two approaches.
DelveInsight's Brain Metastases pipeline analysis reveals a dynamic field featuring more than 40 engaged entities advancing over 45 investigational treatments for Brain Metastases management.
Major Brain Metastases pharmaceutical firms include HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation, among additional organizations.
Notable Brain Metastases Pipeline investigational medications include GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib, among others.
Learn how leading Brain Metastases Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today! - Brain Metastases Clinical Trials Assessment
The Brain Metastases Pipeline Analysis delivers a condition synopsis, pipeline landscape, and therapeutic evaluation of principal investigational therapies within this domain. The analysis also emphasizes unaddressed medical requirements concerning the development of Brain Metastases.
Brain Metastases Background
Brain Metastases Background
Brain metastases are a common complication of cancer and the most prevalent type of brain tumor. Anywhere from 10% to 26% of patients who die from their cancer will develop brain metastases. While few cancers that metastasize to the brain can be cured using conventional therapies, long-term survival and palliation are possible with minimal adverse effects to patients. Increasingly, neuro-cognition and quality of life are being recognized as important endpoints for patients as survival continues to increase.
Brain Metastases Investigational Drug Profiles
Brain Metastases Investigational Drug Profiles
ANG1005: Angiochem
ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem's technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.
Azeliragon: Cantex Pharmaceuticals, Inc.
Azeliragon, is an oral, small molecule, administered once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins, in the tumor microenvironment. Activation of RAGE by these ligands stimulates cancer and its progression and metastasis and resistance to cancer treatment.
AZD3759: Alpha Biopharma Ltd.
Zorifertinib (AZD3759) is a type of reversible new generation EGFR TKI, which has a strong ability to penetrate the bloodstream, cerebrospinal fluid, and can reach blood volume in the tissue. It is currently investigated for brain metastases and completed Phase II/III trial in July 2022.
From early-stage research to late-phase Brain Metastases Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed—download now! - Brain Metastases Treatment Drugs
The Brain Metastases Pipeline Analysis Offers Insights Into
The Brain Metastases Pipeline Analysis Offers Insights Into
The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Brain Metastases management, including cumulative therapies created by each organization for this indication.
It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Brain Metastases Treatment.
Brain Metastases pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.
Brain Metastases investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.
Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Brain Metastases market.
Brain Metastases Pharmaceutical Firms
Brain Metastases Pharmaceutical Firms
HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation, among additional organizations.
The Brain metastases pipeline analysis presents therapeutic evaluation of investigational medications by Administration Method. Products are classified under multiple administration routes including:
Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal
Brain Metastases products are classified under various molecular categories including:
Oligonucleotide Peptide Small molecule
Stay updated with the latest Brain Metastases Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! - Brain Metastases Market Drivers and Barriers, and Future Perspectives
Scope of the Brain Metastases Pipeline Analysis
Scope of the Brain Metastases Pipeline Analysis
Coverage: Global
Brain Metastases Pharmaceutical Firms: HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation, among additional organizations.
Brain Metastases Pipeline Investigational Treatments: GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib, among others.
Brain Metastases Therapeutic Evaluation by Product Category: Monotherapy, Combination, Mono/Combination
Brain Metastases Therapeutic Evaluation by Clinical Phases: Discovery, Preclinical, Phase I, Phase II, Phase III
Find answers in our latest Brain Metastases Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation! - Brain Metastases Emerging Drugs and Companies
Table of Contents
Table of Contents
Introduction
Executive Summary
Brain metastases: Overview
Pipeline Therapeutics
Therapeutic Assessment
Brain metastases– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
ANG1005: Angiochem
Mid Stage Products (Phase II)
Paxalisib: Kazia Therapeutics
Early Stage Products (Phase I)
MW151: ImmunoChem Therapeutics, LLC
Preclinical and Discovery Stage Products
JBI-2174: Jubilant Therapeutics
Inactive Products
Brain metastases Key Companies
Brain metastases Key Products
Brain metastases- Unmet Needs
Brain metastases- Market Drivers and Barriers
Brain metastases- Future Perspectives and Conclusion
Brain metastases Analyst Views
Brain metastases Key Companies
Appendix
About Us
About Us
DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide. Partner with us to obtain superior-quality, precise, and current intelligence to maintain competitive advantage.
Contact Us
Contact Us
Kanishk
Page updated
Google Sites
Report abuse